New drug aims to calm inflammation in kidney dialysis patients
NCT ID NCT07619820
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called CSL300 (clazakizumab) in 24 Chinese adults with end-stage kidney disease who are on dialysis. The drug is an antibody that blocks interleukin-6, a protein involved in inflammation. The main goal is to see how the drug moves through the body and whether it is safe, not yet to measure if it improves health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Clazakizumab (CSL300), a lab-made antibody that blocks interleukin-6, given as an injection
What this could lead to
If successful, this could point toward a new way to reduce inflammation in dialysis patients, potentially improving their long-term outcomes.
What could go wrong
This is a very early (Phase 1b), small (24 people) safety and dosing study. It is not designed to prove the drug works, and side effects like infections are a known risk with this type of drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE (ESKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••